# Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

> **NCT05450965** · PHASE2 · RECRUITING · sponsor: **University of Maryland, Baltimore** · enrollment: 37 (estimated)

## Conditions studied

- Small-cell Lung Cancer
- Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Onvansertib

## Key facts

- **NCT ID:** NCT05450965
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-19
- **Primary completion:** 2027-08-31
- **Final completion:** 2027-11-30
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2025-12-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05450965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05450965, "Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05450965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*